On­copep­tides says a sec­ond look at its da­ta of­fers a win in head-to-head can­cer tri­al — but key OS flop trig­gers a hold

Swe­den’s On­copep­tides has some good news and some bad news to re­port to­day.

The good news is the in­de­pen­dent re­view group over­see­ing a head-to-head study be­tween the biotech’s drug melflufen — ap­proved by the FDA last Feb­ru­ary as a 5th-line treat­ment and sold as Pepax­to — was able to reeval­u­ate the da­ta and de­clare its drug a win­ner on pro­gres­sion-free sur­vival against Po­m­a­lyst (po­ma­lido­mide) among pa­tients with drug-re­sis­tant mul­ti­ple myelo­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER